MOBILE, Ala. / May 01, 2025 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the market closes. The Company will host a conference call at 3:30 p.m. Central Time, 4:30 p.m. Eastern Time the same day. To access this interactive teleconference, dial (888) 396-8049 and request connection to the TruBridge earnings conference call.
A live broadcast of TruBridge’s conference call will also be available online at the Company’s website, www.trubridge.com. The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About TruBridge
We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes. Our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings combine unparalleled visibility and transparency to enhance productivity and support the financial health of healthcare organizations across all care settings. TruBridge has over four decades of experience in connecting providers, patients and communities with innovative solutions that create real value by supporting both the financial and clinical side of healthcare delivery. Our solutions champion end-to-end, data-driven patient journeys that support value-based care, improve outcomes, and increase patient satisfaction. We support efficient patient care with electronic health record (EHR) product offerings that successfully integrate data between care settings. Above all, we believe in the power of community and encourage collaboration, connection, and empowerment with our customers. We clear the way for care. For more information, please visit www.trubridge.com.
Last Trade: | US$19.92 |
Daily Change: | 0.02 0.10 |
Daily Volume: | 5,837 |
Market Cap: | US$298.920M |
October 03, 2025 September 23, 2025 August 07, 2025 May 07, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load